Loading...
•
Dec 31, 2019
Zimmer Biomet Q4 2019 Earnings Report
Zimmer Biomet reported an increase in fourth quarter net sales and provided full-year 2020 guidance.
Key Takeaways
Zimmer Biomet announced fourth quarter net sales of $2.126 billion, a 2.6% increase over the prior year period, and diluted EPS of $1.54. Adjusted diluted EPS were $2.30, a 5.5% increase over the prior year period. The company provided full-year 2020 revenue growth guidance of 2.5% to 3.5%.
Fourth quarter net sales increased 2.6%, 3.2% on a constant currency basis.
Fourth quarter diluted EPS were $1.54; adjusted diluted EPS were $2.30.
Key drivers in the fourth quarter included solid performance from the Americas and Asia Pacific, with continued strong results across our global Knee and Hip businesses.
ROSA® Knee System sales accelerated from the third quarter of 2019.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is providing the following full-year 2020 financial guidance: Company expects 2.5% to 3.5% revenue growth on a reported and constant currency basis.
Positive Outlook
- Company expects 2.5% to 3.5% revenue growth on a reported and constant currency basis
Revenue & Expenses
Visualization of income flow from segment revenue to net income